In Brief: Baxter/Immuno International AG
This article was originally published in The Gray Sheet
Executive Summary
Baxter/Immuno International AG: Federal Trade Commission approves Baxter's proposed $715 mil. acquisition of Zurich, Switzerland-based Immuno, an agreement for which was signed Aug. 28. FTC's approval is conditioned on Baxter's divestiture within four months of its Autoplex T hemophilia A therapy and Immuno granting a nonexclusive U.S. license to its Tisseal fibrin sealant. Baxter completes the first phase of its three-phase transaction by acquiring 54% of the voting interest and 37% of the capital interest in Immuno...